Posted by Michael Wonder on 06 Aug 2017
NICE issues draft guidance on Almirall’s Skilarence for psoriasis
4 August 2017 - NICE, the cost-effectiveness watchdog for England, has issued draft guidance recommending Skilarence (dimethyl fumarate).
Developed by Spanish drug maker Almirall, the drug looks set to be made available on the National Health Service as a treatment for moderate to severe plaque psoriasis.
Dimethyl fumarate is recommended for adults who have not responded to, or cannot take, other systemic non-biological treatments.
